5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5’nucleotides. The 5′ Nucleotidase drugs in development market research report provides an in-depth analysis of 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted pipeline therapeutics. The report provides comprehensive information on the 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.
What are the therapy areas of the 5′ Nucleotidase pipeline drugs market?
The therapy areas of the 5′ Nucleotidase pipeline drugs market are oncology, infectious disease, and respiratory.
5′ Nucleotidase pipeline drugs market, by therapy areas
For more therapy area insights, download a free report sample
What are the indications of the 5′ Nucleotidase pipeline drugs market?
Some of the indications of the 5′ Nucleotidase pipeline drugs market are solid tumor, non-small cell lung cancer, ovarian cancer, unspecified cancer, pancreatic cancer, triple-negative breast cancer (TNBC), colorectal cancer, gastric cancer, head and neck cancer squamous cell carcinoma, and hepatocellular carcinoma.
5′ Nucleotidase pipeline drugs market, by indications
For more indications insights, download a free report sample
What are the mechanisms of action of the 5′ Nucleotidase pipeline drugs market?
The mechanism of action of the 5′ Nucleotidase pipeline drugs market is 5′ Nucleotidase Inhibitor.
What are the routes of administration in the 5′ Nucleotidase pipeline drugs market?
The routes of administration in the 5′ Nucleotidase pipeline drugs market are intravenous, oral, and parenteral.
5′ Nucleotidase pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the 5′ Nucleotidase pipeline drugs market?
The molecule types in the 5′ Nucleotidase pipeline drugs market are monoclonal antibody, small molecule, antibody, antisense RNAi oligonucleotide, and antisense oligonucleotide.
5′ Nucleotidase pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the 5′ Nucleotidase pipeline drugs market?
Some of the key companies in the 5′ Nucleotidase pipeline drugs market are Abbisko Therapeutics Co Ltd, Akeso Inc, Antengene Corp Ltd, Aprilbio Co Ltd, Arcus Biosciences Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, BioArdis LLC, BrightPath Biotherapeutics Co Ltd, and Bristol-Myers Squibb Co.
5′ Nucleotidase pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
Therapy Areas | Oncology, Infectious Disease, and Respiratory |
Indications | Solid Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Unspecified Cancer, Pancreatic Cancer, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Gastric Cancer, Head and Neck Cancer Squamous Cell Carcinoma, and Hepatocellular Carcinoma |
Mechanisms of Action | 5′ Nucleotidase Inhibitor |
Routes of Administration | Intravenous, Oral, and Parenteral |
Molecule Types | Monoclonal Antibody, Small Molecule, Antibody, Antisense RNAi Oligonucleotide, and Antisense Oligonucleotide |
Key Companies | Abbisko Therapeutics Co Ltd, Akeso Inc, Antengene Corp Ltd, Aprilbio Co Ltd, Arcus Biosciences Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, BioArdis LLC, BrightPath Biotherapeutics Co Ltd, and Bristol-Myers Squibb Co |
This report provides:
- A snapshot of the global therapeutic landscape of 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5).
- Reviews of pipeline therapeutics for 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key players involved in 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) therapeutics and enlists all their major and minor projects.
- Assessment of 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Akeso Inc
Antengene Corp Ltd
Aprilbio Co Ltd
Arcus Biosciences Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
BioArdis LLC
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Corvus Pharmaceuticals Inc
Eternity Bioscience Inc
Evotec SE
Harbour BioMed (Guangzhou) Co Ltd
I-Mab
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
InteRNA Technologies BV
iOnctura SA
Jacobio Pharmaceuticals Group Co Ltd
Les Laboratoires Servier SAS
Ligand Pharmaceuticals Inc
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Secarna Pharmaceuticals GmbH & Co KG
Shanghai De Novo Pharmatech Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Henlius Biotech Inc
Symphogen A/S
Trican Biotechnology Co Ltd
Verseon Corp
Zhejiang Borui Biopharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the therapy areas of the 5′ Nucleotidase pipeline drugs market?
The therapy areas of the 5′ Nucleotidase pipeline drugs market are oncology, infectious disease, and respiratory.
-
What are the indications of the 5′ Nucleotidase pipeline drugs market?
Some of the indications of the 5′ Nucleotidase pipeline drugs market are solid tumor, non-small cell lung cancer, ovarian cancer, unspecified cancer, pancreatic cancer, triple-negative breast cancer (TNBC), colorectal cancer, gastric cancer, head and neck cancer squamous cell carcinoma, and hepatocellular carcinoma.
-
What are the mechanisms of action of the 5′ Nucleotidase pipeline drugs market?
The mechanism of action of the 5′ Nucleotidase pipeline drugs market is 5′ Nucleotidase Inhibitor.
-
What are the routes of administration in the 5′ Nucleotidase pipeline drugs market?
The routes of administration in the 5′ Nucleotidase pipeline drugs market are intravenous, oral, and parenteral.
-
What are the molecule types in the 5′ Nucleotidase pipeline drugs market?
The molecule types in the 5′ Nucleotidase pipeline drugs market are monoclonal antibody, small molecule, antibody, antisense RNAi oligonucleotide, and antisense oligonucleotide.
-
Which are the key companies in the 5′ Nucleotidase pipeline drugs market?
Some of the key companies in the 5′ Nucleotidase pipeline drugs market are Abbisko Therapeutics Co Ltd, Akeso Inc, Antengene Corp Ltd, Aprilbio Co Ltd, Arcus Biosciences Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, BioArdis LLC, BrightPath Biotherapeutics Co Ltd, and Bristol-Myers Squibb Co.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.